Abstract
Ovarian cancer is one of the deadliest gynecological malignancies in women. Chemoresistance has been a major obstacle for ovarian cancer treatment. Zinc finger E-box-binding homeobox 1 (ZEB1) is an important regulator of tumor development in various types of cancer. Abnormal expression of SLC3A2 (CD98hc), a type 2 transmembrane cell surface molecule, has been described in several cancers. This study was designed to investigate the role of ZEB1 and SLC3A2 in the chemoresistance to cisplatin in ovarian cancer cells. We found that ZEB1 was increased in cisplatin-resistant SKOV3/DPP cells. Downregulation of ZEB1 significantly decreased cell viability in response to cisplatin, increased cis-platin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin. In addition, downregulation of ZEB1 decreased the volume and weight of implanted tumors. SLC3A2 was decreased in cisplatin-resistant SKOV3/DPP cells. Upregulation of SLC3A2 significantly decreased cell viability in response to cisplatin, increased cisplatin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin. Moreover, upregulation of SLC3A2 decreased the volume and weight of implanted tumors. Downregulation of ZEB1 resulted in a significant increase of SLC3A2 expression. Moreover, downregulation of SLC3A2 significantly inhibited ZEB1 knockdown-mediated inhibition of cisplatin-resistance. ZEB1-mediated regulation of SLC3A2 was involved in the chemoresistance to cisplatin in ovarian cancer cells. Overall, we provide new insights into the mechanism of chemoresistance to cisplatin in ovarian cancer cells. ZEB1/SLC3A2 may be promising therapeutic targets for enhancement of the sensitivity of ovarian cancer cells to cisplatin-mediated chemotherapy.
References
1.
Siegel
RL
, Miller
KD
, Jemal
A
. Cancer Statistics, 2017
. CA Cancer J Clin
. 2017
Jan
;67
(1
):7
–30
.
[PubMed]
0007-92352.
Chen
W
, Zheng
R
, Baade
PD
, Zhang
S
, Zeng
H
, Bray
F
, et al Cancer statistics in China, 2015
. CA Cancer J Clin
. 2016
Mar-Apr
;66
(2
):115
–32
.
[PubMed]
0007-92353.
Vaughan
S
, Coward
JI
, Bast
RC
Jr, Berchuck
A
, Berek
JS
, Brenton
JD
, et al Rethinking ovarian cancer: recommendations for improving outcomes
. Nat Rev Cancer
. 2011
Sep
;11
(10
):719
–25
.
[PubMed]
1474-175X4.
Rescigno
P
, Cerillo
I
, Ruocco
R
, Condello
C
, De Placido
S
, Pensabene
M
. New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches
. BioMed Res Int
. 2013
;2013
:852839
.
[PubMed]
2314-61335.
Luvero
D
, Milani
A
, Ledermann
JA
. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
. Ther Adv Med Oncol
. 2014
Sep
;6
(5
):229
–39
.
[PubMed]
1758-83406.
Ozols
RF
, Bundy
BN
, Greer
BE
, Fowler
JM
, Clarke-Pearson
D
, Burger
RA
, et al; Gynecologic Oncology Group
. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study
. J Clin Oncol
. 2003
Sep
;21
(17
):3194
–200
.
[PubMed]
0732-183X7.
Sánchez-Tilló
E
, Siles
L
, de Barrios
O
, Cuatrecasas
M
, Vaquero
EC
, Castells
A
, et al Expanding roles of ZEB factors in tumorigenesis and tumor progression
. Am J Cancer Res
. 2011
;1
(7
):897
–912
.
[PubMed]
2156-69768.
An
J
, Lv
W
, Zhang
Y
. LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194
. OncoTargets Ther
. 2017
Nov
;10
:5377
–90
.
[PubMed]
1178-69309.
Chung
VY
, Tan
TZ
, Tan
M
, Wong
MK
, Kuay
KT
, Yang
Z
, et al GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification
. Sci Rep
. 2016
Feb
;6
(1
):19943
.
[PubMed]
2045-232210.
Jin
M
, Yang
Z
, Ye
W
, Xu
H
, Hua
X
. MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1
. PLoS One
. 2014
Aug
;9
(8
):e103965
.
[PubMed]
1932-620311.
Niu
K
, Shen
W
, Zhang
Y
, Zhao
Y
, Lu
Y
. MiR-205 promotes motility of ovarian cancer cells via targeting ZEB1
. Gene
. 2015
Dec
;574
(2
):330
–6
.
[PubMed]
0378-111912.
Chen
D
, Wang
J
, Zhang
Y
, Chen
J
, Yang
C
, Cao
W
, Zhang
H
, Liu
Y
, Dou
J
: Effect of down-regulated transcriptional repressor ZEB1 on the epithelial-mesenchymal transition of ovarian cancer cells.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2013
;23:1357-1366.13.
Hu
C
, Dong
T
, Li
R
, Lu
J
, Wei
X
, Liu
P
. Emodin inhibits epithelial to mesenchymal transition in epithelial ovarian cancer cells by regulation of GSK-3β/β-catenin/ZEB1 signaling pathway
. Oncol Rep
. 2016
Apr
;35
(4
):2027
–34
.
[PubMed]
1021-335X14.
Zou
J
, Liu
L
, Wang
Q
, Yin
F
, Yang
Z
, Zhang
W
, et al Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1
. Am J Transl Res
. 2017
Mar
;9
(3
):1357
–68
.
[PubMed]
1943-814115.
Zhang
X
, Zhang
Z
, Zhang
Q
, Zhang
Q
, Sun
P
, Xiang
R
, et al ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM
. Cell Death Dis
. 2018
Jan
;9
(2
):57
.
[PubMed]
2041-488916.
Dixon
WT
, Sikora
LK
, Demetrick
DJ
, Jerry
LM
. Isolation and characterization of a heterodimeric surface antigen on human melanoma cells and evidence that it is the 4F2 cell activation/proliferation molecule
. Int J Cancer
. 1990
Jan
;45
(1
):59
–68
.
[PubMed]
0020-713617.
Esteban
F
, Ruiz-Cabello
F
, Concha
A
, Perez Ayala
M
, Delgado
M
, Garrido
F
. Relationship of 4F2 antigen with local growth and metastatic potential of squamous cell carcinoma of the larynx
. Cancer
. 1990
Oct
;66
(7
):1493
–8
.
[PubMed]
0008-543X18.
Garber
ME
, Troyanskaya
OG
, Schluens
K
, Petersen
S
, Thaesler
Z
, Pacyna-Gengelbach
M
, et al Diversity of gene expression in adenocarcinoma of the lung
. Proc Natl Acad Sci USA
. 2001
Nov
;98
(24
):13784
–9
.
[PubMed]
0027-842419.
Wang
S
, Han
H
, Hu
Y
, Yang
W
, Lv
Y
, Wang
L
, et al SLC3A2, antigen of mAb 3G9, promotes migration and invasion by upregulating of mucins in gastric cancer
. Oncotarget
. 2017
Jul
;8
(51
):88586
–98
.
[PubMed]
1949-255320.
Prager
GW
, Poettler
M
, Schmidinger
M
, Mazal
PR
, Susani
M
, Zielinski
CC
, et al CD98hc (SLC3A2), a novel marker in renal cell cancer
. Eur J Clin Invest
. 2009
Apr
;39
(4
):304
–10
.
[PubMed]
0014-297221.
Verrey
F
, Closs
EI
, Wagner
CA
, Palacin
M
, Endou
H
, Kanai
Y
. CATs and HATs: the SLC7 family of amino acid transporters
. Pflugers Arch
. 2004
Feb
;447
(5
):532
–42
.
[PubMed]
0031-676822.
Prager
GW
, Féral
CC
, Kim
C
, Han
J
, Ginsberg
MH
. CD98hc (SLC3A2) interaction with the integrin beta subunit cytoplasmic domain mediates adhesive signaling
. J Biol Chem
. 2007
Aug
;282
(33
):24477
–84
.
[PubMed]
0021-925823.
Wu
D
, Lu
P
, Mi
X
, Miao
J
. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85
. Arch Gynecol Obstet
. 2018
Mar
;297
(3
):699
–707
.
[PubMed]
0932-006724.
Sankaranarayanan
R
, Ferlay
J
. Worldwide burden of gynaecological cancer: the size of the problem
. Best Pract Res Clin Obstet Gynaecol
. 2006
Apr
;20
(2
):207
–25
.
[PubMed]
1521-693425.
Zhu
B
, Cheng
D
, Hou
L
, Zhou
S
, Ying
T
, Yang
Q
. SLC3A2 is upregulated in human osteosarcoma and promotes tumor growth through the PI3K/Akt signaling pathway
. Oncol Rep
. 2017
May
;37
(5
):2575
–82
.
[PubMed]
1021-335X26.
Fei
F
, Li
X
, Xu
L
, Li
D
, Zhang
Z
, Guo
X
, et al CD147-CD98hc complex contributes to poor prognosis of non-small cell lung cancer patients through promoting cell proliferation via the PI3K/Akt signaling pathway
. Ann Surg Oncol
. 2014
Dec
;21
(13
):4359
–68
.
[PubMed]
1068-926527.
Mabuchi
S
, Kuroda
H
, Takahashi
R
, Sasano
T
. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
. Gynecol Oncol
. 2015
Apr
;137
(1
):173
–9
.
[PubMed]
0090-825828.
Cheaib
B
, Auguste
A
, Leary
A
. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
. Chin J Cancer
. 2015
Jan
;34
(1
):4
–16
.
[PubMed]
1000-467X29.
Li
H
, Zeng
J
, Shen
K
. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
. Arch Gynecol Obstet
. 2014
Dec
;290
(6
):1067
–78
.
[PubMed]
0932-0067© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
